The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...
Hosted on MSN7m
UNAIDS Calls On Leaders At Davos To Commit To Rapid Global Access To Revolutionary New Long-Acting HIV MedicinesUNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...
It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...
Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...
Hosted on MSN15h
Can Gilead Sciences Sustain Its Growth Momentum in 2025?Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...
Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...
Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback